Westhampton Capital LLC Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Westhampton Capital LLC raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 893 shares of the biopharmaceutical company’s stock after purchasing an additional 15 shares during the quarter. Westhampton Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $939,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Gateway Investment Advisers LLC grew its holdings in Regeneron Pharmaceuticals by 13.7% during the 1st quarter. Gateway Investment Advisers LLC now owns 1,337 shares of the biopharmaceutical company’s stock valued at $1,287,000 after purchasing an additional 161 shares in the last quarter. West Paces Advisors Inc. grew its stake in shares of Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 23 shares in the last quarter. Wealthcare Advisory Partners LLC increased its position in shares of Regeneron Pharmaceuticals by 14.4% during the first quarter. Wealthcare Advisory Partners LLC now owns 294 shares of the biopharmaceutical company’s stock worth $283,000 after acquiring an additional 37 shares during the last quarter. Signet Financial Management LLC boosted its holdings in Regeneron Pharmaceuticals by 2.0% in the first quarter. Signet Financial Management LLC now owns 4,020 shares of the biopharmaceutical company’s stock valued at $3,870,000 after purchasing an additional 78 shares during the last quarter. Finally, Janiczek Wealth Management LLC grew its stake in Regeneron Pharmaceuticals by 20.1% during the 1st quarter. Janiczek Wealth Management LLC now owns 221 shares of the biopharmaceutical company’s stock valued at $213,000 after purchasing an additional 37 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, VP Jason Pitofsky sold 487 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares in the company, valued at $4,498,280. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Trading Down 0.6 %

Shares of NASDAQ:REGN opened at $962.34 on Wednesday. The company has a 50 day moving average of $1,102.60 and a 200-day moving average of $1,041.37. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The firm has a market cap of $106.09 billion, a P/E ratio of 25.49, a P/E/G ratio of 3.40 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a twelve month low of $769.19 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. During the same period last year, the company posted $8.79 EPS. The firm’s quarterly revenue was up 12.3% on a year-over-year basis. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on REGN. Leerink Partners reaffirmed a “market perform” rating and issued a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Piper Sandler increased their price objective on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research note on Friday, August 23rd. Wells Fargo & Company dropped their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday. Morgan Stanley reduced their price target on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Finally, Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,108.86.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.